# Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)

> **NCT00508833** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 200 (estimated)

## Conditions studied

- Hepatitis B Disease

## Interventions

- **BIOLOGICAL:** 287615 containing HBsAg with adjuvants

## Key facts

- **NCT ID:** NCT00508833
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2007-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508833, "Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00508833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*